OMAHA, Neb. (WOWT) - The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or Zepbound were previously in a shortage.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

The injectable drug Ozempic is shown Saturday ... 503A and 503B, based on the FDA regulations that govern their operations. The latter is impacted by the ruling, according to industry experts.

Though Noom says the approach complies with FDA regulations allowing personalized ... to increase manufacturing capacity of Wegovy and Ozempic, a GLP-1 approved for patients with Type 2 diabetes.

Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...

That means they can make a version of semaglutide that is not identical or nearly identical to Ozempic and Wegovy ... and follow applicable FDA rules and regulations on compounding." ...

The end of copycat weight-loss drugs When the Food and Drug Administration ... loss drugs Ozempic and Wegovy. There are still ways that companies can get around the compounding regulations and ...